Hypersensitivity reactions (HSRs) represent an adverse immunological response ranging from mild cutaneous eruptions to severe, potentially fatal anaphylaxis. These reactions are particularly ...

1 Department of Microbiology & Immunology, The University of Melbourne, Parkville, Victoria 3010, Australia. An increasing number of HLA associations have been observed with drug-hypersensitivity ...

—An analysis of registry data concluded that hypersensitivity reactions in patients with mastocytosis are caused by exposure to certain triggers, including low tryptase levels and stings from certain ...

Hypersensitivity reactions to vaccines occur in 1 in 50,000 to 1 in 100,000 doses. Most are local reactions and allow for the completion of the vaccination series. Systemic reactions are a minority ...

Adverse drug reactions (ADRs) encompass a wide spectrum of unintended and harmful responses to medications, with hypersensitivity syndromes representing some of the most severe and potentially ...

An international expert consensus offers guidance to diagnose, assess, and treat adult patients experiencing drug reaction with eosinophilia and systemic symptoms (DRESS). Data on the evaluation, ...

Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma Efficacy of ...

Predictors of survival in patients with refractory metastatic colorectal cancer. Background: The incidence of hypersensitivity reactions (HSRs) to oxaliplatin (L-OHP ...

Credit: Getty Images. The IGIV and IGSC products were voluntarily withdrawn due to a higher rate of allergic/hypersensitivity type reactions, some of which were considered medically significant.

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a T-cell–mediated severe cutaneous adverse reaction characterized by rash, fever, internal organ involvement, and systemic ...

FDA approved zenocutuzumab-zbco for post-systemic-therapy, NRG1 fusion–positive unresectable/metastatic cholangiocarcinoma, addressing an ultra-rare molecular ...